• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Rifaximin in the spotlight: Are we ready to target the microbiome?

作者信息

Artru Florent, Hernández-Gea Virginia

机构信息

Liver Department, Rennes University Hospital and Rennes University, France.

NuMeCan Institute INSERM UMR 1241, France.

出版信息

JHEP Rep. 2025 Apr 1;7(5):101360. doi: 10.1016/j.jhepr.2025.101360. eCollection 2025 May.

DOI:10.1016/j.jhepr.2025.101360
PMID:40452949
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12126948/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aae3/12126948/982e98618bc5/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aae3/12126948/982e98618bc5/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aae3/12126948/982e98618bc5/gr1.jpg

相似文献

1
Rifaximin in the spotlight: Are we ready to target the microbiome?利福昔明成为焦点：我们准备好针对微生物群了吗？
JHEP Rep. 2025 Apr 1;7(5):101360. doi: 10.1016/j.jhepr.2025.101360. eCollection 2025 May.
2
Rifaximin-mediated gut microbiota regulation modulates the function of microglia and protects against CUMS-induced depression-like behaviors in adolescent rat.利福昔明介导的肠道微生物群调节可调节小胶质细胞的功能，并预防 CUMS 诱导的青春期大鼠抑郁样行为。
J Neuroinflammation. 2021 Nov 4;18(1):254. doi: 10.1186/s12974-021-02303-y.
3
Detrimental Effect of Broad-spectrum Antibiotics on Intestinal Microbiome Diversity in Patients After Allogeneic Stem Cell Transplantation: Lack of Commensal Sparing Antibiotics.异基因造血干细胞移植后广谱抗生素对肠道微生物多样性的有害影响：缺乏共生保护抗生素。
Clin Infect Dis. 2019 Apr 8;68(8):1303-1310. doi: 10.1093/cid/ciy711.
4
Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity.利福昔明改善肝性脑病和内毒素血症而不影响肠道微生物多样性。
World J Gastroenterol. 2017 Dec 21;23(47):8355-8366. doi: 10.3748/wjg.v23.i47.8355.
5
Rifaximin Ameliorates Non-alcoholic Steatohepatitis in Mice Through Regulating gut Microbiome-Related Bile Acids.利福昔明通过调节肠道微生物群相关胆汁酸改善小鼠非酒精性脂肪性肝炎。
Front Pharmacol. 2022 Apr 4;13:841132. doi: 10.3389/fphar.2022.841132. eCollection 2022.
6
RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.利福昔明对肝硬化患者轻微肝性脑病（MHE）及肠道微生物群的影响：一项随机对照试验的研究方案
Trials. 2016 Feb 29;17(1):111. doi: 10.1186/s13063-016-1205-8.
7
Eubiotic effect of rifaximin is associated with decreasing abdominal pain in symptomatic uncomplicated diverticular disease: results from an observational cohort study.利福昔明的生态效应与症状性单纯性憩室病腹痛减轻有关：来自观察性队列研究的结果。
BMC Gastroenterol. 2023 Mar 23;23(1):82. doi: 10.1186/s12876-023-02690-x.
8
Effects of Rifaximin on Transit, Permeability, Fecal Microbiome, and Organic Acid Excretion in Irritable Bowel Syndrome.利福昔明对肠易激综合征患者肠道转运、通透性、粪便微生物群及有机酸排泄的影响
Clin Transl Gastroenterol. 2016 May 26;7(5):e173. doi: 10.1038/ctg.2016.32.
9
Rifaximin treatment shapes a unique metagenome-metabolism network in patients with decompensated cirrhosis.利福昔明治疗可重塑肝硬化失代偿期患者独特的宏基因组-代谢网络。
J Gastroenterol Hepatol. 2024 Apr;39(4):762-771. doi: 10.1111/jgh.16484. Epub 2024 Jan 17.
10
Gastrointestinal (non-systemic) antibiotic rifaximin differentially affects chronic stress-induced changes in colon microbiome and gut permeability without effect on behavior.胃肠道（非系统性）抗生素利福昔明可改变慢性应激诱导的结肠微生物组和肠道通透性的变化，但对行为无影响。
Brain Behav Immun. 2020 Feb;84:218-228. doi: 10.1016/j.bbi.2019.12.004. Epub 2019 Dec 7.

本文引用的文献

1
The burden of hepatic encephalopathy and the use of albumin as a potential treatment.肝性脑病的负担以及白蛋白作为一种潜在治疗方法的应用。
Ann Hepatol. 2025 Jan-Jun;30(1):101751. doi: 10.1016/j.aohep.2024.101751. Epub 2024 Dec 3.
2
Rifaximin prophylaxis causes resistance to the last-resort antibiotic daptomycin.利福昔明预防会导致对最后手段抗生素达托霉素产生耐药性。
Nature. 2024 Nov;635(8040):969-977. doi: 10.1038/s41586-024-08095-4. Epub 2024 Oct 23.
3
Global burden of liver disease: 2023 update.全球肝病负担：2023 年更新。
J Hepatol. 2023 Aug;79(2):516-537. doi: 10.1016/j.jhep.2023.03.017. Epub 2023 Mar 27.
4
Rectal colonization by resistant bacteria increases the risk of infection by the colonizing strain in critically ill patients with cirrhosis.肝硬化危重症患者肠道定植耐药菌会增加定植菌感染的风险。
J Hepatol. 2022 May;76(5):1079-1089. doi: 10.1016/j.jhep.2021.12.042. Epub 2022 Jan 22.
5
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.2019 年全球细菌对抗菌药物耐药性的负担：系统分析。
Lancet. 2022 Feb 12;399(10325):629-655. doi: 10.1016/S0140-6736(21)02724-0. Epub 2022 Jan 19.
6
Cirrhosis-associated immune dysfunction.肝硬化相关免疫功能障碍。
Nat Rev Gastroenterol Hepatol. 2022 Feb;19(2):112-134. doi: 10.1038/s41575-021-00520-7. Epub 2021 Oct 26.
7
The Use of Rifaximin in the Prevention of Overt Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt : A Randomized Controlled Trial.利福昔明在经颈静脉肝内门体分流术后预防显性肝性脑病中的应用：一项随机对照试验。
Ann Intern Med. 2021 May;174(5):633-640. doi: 10.7326/M20-0202. Epub 2021 Feb 2.
8
Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide.全球肝硬化患者细菌感染的流行病学和影响。
Gastroenterology. 2019 Apr;156(5):1368-1380.e10. doi: 10.1053/j.gastro.2018.12.005. Epub 2018 Dec 13.
9
EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis.欧洲肝脏研究学会失代偿期肝硬化患者管理临床实践指南
J Hepatol. 2018 Aug;69(2):406-460. doi: 10.1016/j.jhep.2018.03.024. Epub 2018 Apr 10.
10
A risk score to predict the development of hepatic encephalopathy in a population-based cohort of patients with cirrhosis.一种用于预测肝硬化患者人群中肝性脑病发展的风险评分。
Hepatology. 2018 Oct;68(4):1498-1507. doi: 10.1002/hep.29628. Epub 2018 May 14.